Antiviral activity of Bifidobacterium adolescentis SPM0212 against Hepatitis B virus

2013 ◽  
Vol 36 (12) ◽  
pp. 1525-1532 ◽  
Author(s):  
Do Kyung Lee ◽  
Joo Yeon Kang ◽  
Hea Soon Shin ◽  
Il Ho Park ◽  
Nam Joo Ha
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Antiviral Activity ◽  
Bifidobacterium Adolescentis ◽  
B Virus

scholarly journals Possible role of tocopherols in the modulation of host microRNA with potential antiviral activity in patients with hepatitis B virus-related persistent infection: a systematic review

2014 ◽  
Vol 112 (11) ◽  
pp. 1751-1768 ◽  
Author(s):  
S. Fiorino ◽  
L. Bacchi-Reggiani ◽  
S. Sabbatani ◽  
F. Grizzi ◽  
L. di Tommaso ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Antiviral Activity ◽  
Hbv Infection ◽  
Cochrane Library ◽  
Viral Pathogen ◽  
Increased Risk ◽  
B Virus ◽  
Chronic Hbv

Hepatitis B virus (HBV) infection represents a serious global health problem and persistent HBV infection is associated with an increased risk of cirrhosis, hepatocellular carcinoma and liver failure. Recently, the study of the role of microRNA (miRNA) in the pathogenesis of HBV has gained considerable interest as well as new treatments against this pathogen have been approved. A few studies have investigated the antiviral activity of vitamin E (VE) in chronic HBV carriers. Herein, we review the possible role of tocopherols in the modulation of host miRNA with potential anti-HBV activity. A systematic research of the scientific literature was performed by searching the MEDLINE, Cochrane Library and EMBASE databases. The keywords used were ‘HBV therapy’, ‘HBV treatment’, ‘VE antiviral effects’, ‘tocopherol antiviral activity’, ‘miRNA antiviral activity’ and ‘VE microRNA’. Reports describing the role of miRNA in the regulation of HBV life cycle,in vitroandin vivoavailable studies reporting the effects of VE on miRNA expression profiles and epigenetic networks, and clinical trials reporting the use of VE in patients with HBV-related chronic hepatitis were identified and examined. Based on the clinical results obtained in VE-treated chronic HBV carriers, we provide a reliable hypothesis for the possible role of this vitamin in the modulation of host miRNA profiles perturbed by this viral pathogen and in the regulation of some cellular miRNA with a suggested potential anti-HBV activity. This approach may contribute to the improvement of our understanding of pathogenetic mechanisms involved in HBV infection and increase the possibility of its management and treatment.

scholarly journals Smc5/6-antagonism by HBx is an evolutionary-conserved function of hepatitis B virus infection in mammals

2017 ◽  
Author(s):  
Fabien Filleton ◽  
Fabien Abdul ◽  
Laetitia Gerossier ◽  
Alexia Paturel ◽  
Janet Hall ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Antiviral Activity ◽  
Positive Selection ◽  
Host Species ◽  
Human Hepatocytes ◽  
Arms Race ◽  
Restriction Factor ◽  
Primary Human Hepatocytes ◽  
B Virus

AbstractInfection with Hepatitis B virus (HBV) is a major cause of liver disease and cancer in humans. HBVs (family Hepadnaviridae) have been associated with mammals for millions of years. Recently, the Smc5/6 complex, known for its essential housekeeping functions in genome maintenance, was identified as an antiviral restriction factor of human HBV. The virus has however developed a counteraction mechanism by degrading the complex via its regulatory HBx protein. Whether the antiviral activity of the Smc5/6 complex against hepadnaviruses is an important and evolutionary-conserved function is unknown. Here, we used a combined evolutionary and functional approach to address this question. We first performed phylogenetic and positive selection analyses of the six Smc5/6 complex subunits and found that they have been highly conserved in primates and mammals. Yet, the Smc6 subunit showed marks of adaptive evolution, potentially reminiscent of virus-host “arms-race” We then functionally tested the HBx from six very divergent hepadnaviruses now naturally infecting primates, rodents, and bats. Despite little sequence homology, we demonstrate that these HBx efficiently degraded mammalian Smc5/6 complexes, independently of the host species and of the sites under positive selection. Importantly, all also rescued the replication of an HBx-deficient HBV in primary human hepatocytes. These findings point to an evolutionary-conserved requirement for Smc5/6 inactivation by HBx, showing that the Smc5/6 antiviral activity has been an important defense mechanism against hepadnaviruses in mammals. Interestingly, Smc5/6 may further be a restriction factor of other yet unidentified viruses that have driven some of its adaptation.ImportanceInfection with hepatitis B virus (HBV) led to 887000 human deaths in 2015. HBV has been co-evolving with mammals for millions of years. Recently, the Smc5/6 complex, known for its essential housekeeping functions, was identified as a restriction factor of human HBV antagonized by the regulatory HBx protein. Here, we address whether the antiviral activity of Smc5/6 is an important evolutionary-conserved function. We found that all six subunits of Smc5/6 have been conserved in primates with only Smc6 showing signatures of “evolutionary arms-race” Using evolutionary-guided functional assays that include infections of primary human hepatocytes, we demonstrate that HBx from very divergent mammalian HBVs could all efficiently antagonize Smc5/6, independently of the host species and sites under positive selection. These findings show that the Smc5/6 antiviral activity against HBV is an important function in mammals. It also raises the intriguing possibility that Smc5/6 restricts other, yet unidentified viruses.

Antiviral activity of 5′-O-carbonate-2′,3′-dideoxy-3′-thiacytidine prodrugs against hepatitis B virus in HepG2 2.2.15 cells

2010 ◽  
Vol 36 (6) ◽  
pp. 566-569 ◽  
Author(s):  
Dolores Gagey ◽  
Soledad Ravetti ◽  
Eliana F. Castro ◽  
María Soledad Gualdesi ◽  
Margarita C. Briñon ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Antiviral Activity ◽  
B Virus ◽  
Hepg2 2.2.15

Anti-Hepatitis B Virus Activity of New 1,2,4-Triazol-2-yl- and 1,3,4-Oxadiazol-2-yl-2-pyridinone Derivatives

2008 ◽  
Vol 63 (9-10) ◽  
pp. 667-674 ◽  
Author(s):  
Farag A. El-Essawy ◽  
Wael A. El-Sayed ◽  
Sherif A. El-Kafrawy ◽  
Asmaa S. Morshedy ◽  
Adel-H. Abdel-Rahman
Keyword(s):  
Sulfuric Acid ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Antiviral Activity ◽  
Alkylating Agents ◽  
Acid Hydrazide ◽  
Virus Activity ◽  
B Virus ◽  
Thiadiazole Derivative ◽  
High Antiviral Activity

A number of 1,3,4-oxadiazole, 3 - 9, and 1,2,4-triazole derivatives, 13 - 15, were synthesized starting form the acid hydrazide 1. The 1,3,4-thiadiazole derivative 12 was prepared from the substituted phenylthiosemicarbazide derivative 11 by treatment with sulfuric acid. The aryl hydrazone derivatives 10a - c were synthesized by reaction of the hydrazide 1 with the corresponding ketones. The thioalkyl derivatives 16a - e were prepared by akylation of the thiol derivatives 3 and 13 with different alkylating agents. The newly synthesized compounds were tested for their anti-HBV activity and some of these compounds showed high antiviral activity

Synthesis and antiviral activity of new acrylamide derivatives containing 1,2,3-thiadiazole as inhibitors of hepatitis B virus replication

2010 ◽  
Vol 45 (5) ◽  
pp. 1919-1926 ◽  
Author(s):  
Wei-Li Dong ◽  
Zheng-Xiao Liu ◽  
Xing-Hai Liu ◽  
Zheng-Ming Li ◽  
Wei-Guang Zhao
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Antiviral Activity ◽  
Virus Replication ◽  
B Virus

scholarly journals 3-Hydroxypyrimidine-2,4-Diones as Novel Hepatitis B Virus Antivirals Targeting the Viral Ribonuclease H

2017 ◽  
Vol 61 (6) ◽  
Author(s):  
Andrew D. Huber ◽  
Eleftherios Michailidis ◽  
Jing Tang ◽  
Maritza N. Puray-Chavez ◽  
Maria Boftsi ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Antiviral Activity ◽  
Essential Role ◽  
Rnase H ◽  
Ribonuclease H ◽  
Hbv Replication ◽  
B Virus ◽  
Infected Cells ◽  
Micromolar Range

ABSTRACT Hepatitis B virus (HBV) RNase H (RNH) is an appealing therapeutic target due to its essential role in viral replication. RNH inhibitors (RNHIs) could help to more effectively control HBV infections. Here, we report 3-hydroxypyrimidine-2,4-diones as novel HBV RNHIs with antiviral activity. We synthesized and tested 52 analogs and found 4 that inhibit HBV RNH activity in infected cells. Importantly, 2 of these compounds inhibited HBV replication in the low micromolar range.

578 HEPATITIS B VIRUS INDUCES INTERLEUKIN-8 PRODUCTION WHICH IN TURN INHIBITS INTERFERON- ALFA ANTIVIRAL ACTIVITY IN HEPATOMA CELL LINES

2009 ◽  
Vol 50 ◽  
pp. S213
Author(s):  
T. Pollicino ◽  
L. Bellinghieri ◽  
G. Raffa ◽  
A. Restuccia ◽  
D. Teti ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Antiviral Activity ◽  
Cell Lines ◽  
Hepatoma Cell ◽  
Interferon Alfa ◽  
Interleukin 8 ◽  
Hepatoma Cell Lines ◽  
B Virus

scholarly journals Structure-Activity Relationship of a New Class of Anti-Hepatitis B Virus Agents

2002 ◽  
Vol 46 (12) ◽  
pp. 4004-4008 ◽  
Author(s):  
Anand Mehta ◽  
Bertha Conyers ◽  
D. L. J. Tyrrell ◽  
Kathie-Anne Walters ◽  
Graham A. Tipples ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Antiviral Activity ◽  
Head Group ◽  
New Class ◽  
Chemical Structures ◽  
B Virus ◽  
Ymdd Motif ◽  
Sugar Derivatives ◽  
Relationship Of

ABSTRACT N-Nonyl-deoxy-galactonojirimycin (N-nonyl-DGJ) has been shown to reduce the amount of hepatitis B virus (HBV) produced by tissue cultures under conditions where cell viability is not affected. We show here that the compound N-nonyl-DGJ was effective against lamivudine-resistant HBV mutants bearing the YMDD motif in the polymerase gene, consistent with the compound's activity being distinct from those of nucleoside inhibitors. To better understand the chemical structures that influence its antiviral activity, a series of imino sugar derivatives were made and tested for their antiviral activity against HBV. This work suggests that the antiviral activity of the alkovirs requires an alkyl chain length of at least eight carbons but that the galactose-based head group can be modified with little or no loss in activity.

Sign in / Sign up

Export Citation Format

Share Document